United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates

After the placebo-controlled extension of the pivotal US trial of glatirame r acetate for the treatment of relapsing multiple sclerosis ended, 208 part icipants entered on open-label, long-term treatment protocol. Magnetic reso nance imaging (MRI) was added to the planned evaluations of these subjects to determine the consequences of long-term treatment on MRI-defined patholo gy and evaluate its clinical correlates Of the 147 subjects that remained o n long-term follow-up, adequate images were obtained on 135 for quantitativ e MRI analysis. The initial imaging sessions were Performed between June 19 98 and January 1999 at 2447 +/- 61 days (mean +/- standard deviation) after the subject's original randomization. Clinical data from a preplanned clin ical visit were matched to MRI within 3 +/- 51 days. At imaging, 66 patient s originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1476 +/- 63 days, and 69 randomized to active treat ment with glatiramer acetate (oGA) were on drug for 2433 +/- 59 days. The n umber of documented relapses in the 2 years prior to entering the open-labe l extension was higher in the group originally randomized to placebo (oPBO= 1.86 +/-1.78, oGA=1.03 +/-1.28; P=0.002). The annualized relapse rate obser ved during the open-label study was similar for both groups (oPBO=0.27 +/- 0.45 oGA=0.28 +/-0.40), but the reduction in rate from the Placebo-controll ed phase was greater for those beginning therapy with GA (oPBO reduced by 0 .66 +/-0.71, oGA reduced by 0.23 +/-0.58; P=0.0002). One or more gadolinium enhancing lesions were found in 27.4% of all patients (number of distinct enhancements=1.16 +/-2.52, total enhanced tissue volume=97 +/- 26 mul). The risk of having on enhancement was higher in those with relapses during the open-label extension (odds ratio 4.65, 95% confidence interval (CI) 2.0 to 10.7; P=0.001). The odds for finding on enhancement was 2.5 times higher f or those patients originally randomized to placebo (CI 1.1 to 5.4; P=0.02) compared to those always on glatiramer acetate. MRI-metrics indicative of c hronic pathology, particularly measures of global cerebral tissue loss (atr ophy), were uniformly worse for those originally on placebo. These observat ions enrich our long-term follow up of the clinical consequences of treatme nt with glatiramer acetate to include its apparent effects on MRI-defined p athology. They show that the effect of glatiramer acetate on enhancements i s definite, but modest, consistent with the drug's described mechanisms of action, and that a delay in initiating treatment results in progression of MRI-measured pathology that con be prevented.